A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data
- PMID: 18950670
- DOI: 10.1016/j.vaccine.2008.10.006
A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data
Abstract
The need for developing a case definition and guidelines for a local reaction at or near the injection site, methods for the development of the case definition and guidelines as an adverse event following immunization as well as the rationale for selected decisions about the case definition for a local reaction at or near the injection site are explained in the Preamble section. The case definition is structured in 2 levels of diagnostic certainty: level 1 includes any description of morphological or physiological change at or near the injection site that is described or identified by a healthcare provider. Level 2 is any description of morphological or physiological change at or near injection site that is described by any other person. In Guidelines section, the working group recommends to enable meaningful and standardized data collection, analysis, and presentation of information about a local reaction at or near the injection site. However, implementation of all guidelines might not be possible in all settings. The availability of information may vary depending upon resources, geographic region, and whether the source of information is a prospectively designed clinical trial, a post-marketing surveillance or epidemiologic study, or an individual report of a local reaction at injection site.
Similar articles
-
Induration at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data.Vaccine. 2007 Aug 1;25(31):5839-57. doi: 10.1016/j.vaccine.2007.04.062. Epub 2007 May 8. Vaccine. 2007. PMID: 17553602 No abstract available.
-
Swelling at or near injection site: case definition and guidelines for collection, analysis and presentation of immunization safety data.Vaccine. 2007 Aug 1;25(31):5858-74. doi: 10.1016/j.vaccine.2007.04.056. Epub 2007 May 11. Vaccine. 2007. PMID: 17548132 No abstract available.
-
Abscess at injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data.Vaccine. 2007 Aug 1;25(31):5821-38. doi: 10.1016/j.vaccine.2007.04.057. Epub 2007 May 11. Vaccine. 2007. PMID: 17540485 No abstract available.
-
Nodule at injection site as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation.Vaccine. 2004 Jan 26;22(5-6):575-85. doi: 10.1016/j.vaccine.2003.09.005. Vaccine. 2004. PMID: 14741147 Review. No abstract available.
-
Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation.Vaccine. 2004 Jan 26;22(5-6):551-6. doi: 10.1016/j.vaccine.2003.09.007. Vaccine. 2004. PMID: 14741143 Review. No abstract available.
Cited by
-
Statistical analysis plan for the OPTIMUM study: optimising immunisation using mixed schedules, an adaptive randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine schedule.Trials. 2022 Feb 7;23(1):121. doi: 10.1186/s13063-021-05874-6. Trials. 2022. PMID: 35130946 Free PMC article. Clinical Trial.
-
Safety surveillance of meningococcal group B vaccine (Bexsero®), Vaccine Adverse Event Reporting System, 2015-2018.Vaccine. 2022 Jan 21;40(2):247-254. doi: 10.1016/j.vaccine.2021.11.071. Epub 2021 Dec 7. Vaccine. 2022. PMID: 34887130 Free PMC article.
-
Tolerability of MenACWY-TT vaccination in adolescents in the Netherlands; a cross-sectional study.BMC Public Health. 2021 Sep 26;21(1):1752. doi: 10.1186/s12889-021-11767-9. BMC Public Health. 2021. PMID: 34565374 Free PMC article.
-
OPTIMUM study protocol: an adaptive randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine schedule.BMJ Open. 2020 Dec 17;10(12):e042838. doi: 10.1136/bmjopen-2020-042838. BMJ Open. 2020. PMID: 33334840 Free PMC article.
-
Safety Surveillance of Bivalent Meningococcal Group B Vaccine, Vaccine Adverse Event Reporting System, 2014-2018.Open Forum Infect Dis. 2020 Oct 27;7(12):ofaa516. doi: 10.1093/ofid/ofaa516. eCollection 2020 Dec. Open Forum Infect Dis. 2020. PMID: 33324721 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical